Agalsidase beta biosimilar (GENERIUM Pharmaceuticals)

阿加糖酶β生物类似药 (GENERIUM Pharmaceuticals)

Report date: 2024/04/23 10:49:14

Base Information

Drug NameAgalsidase beta biosimilar (GENERIUM Pharmaceuticals)

Drug Alias NameGEN-062

ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzymeBiologics > Biosimilar

Mechanisms of Actionglycosphingolipid hydrolysis activatorsglobotriaosylceramide (GL-3) hydrolysisα-Galactosidase replacements

TargetsGlycosphingolipidα-Galactosidase

Therapy Area/IndicationsFabry Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGenerium Pharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesGenerium Pharmaceuticals

Inactive CompaniesN/A

Active IndicationsFabry Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A